2019 SciTech Lecture Series: The Ingredients for Innovation in Clinical Research
Name:
2019 SciTech Lecture Series: The Ingredients for Innovation in Clinical Research
Date:
October 31, 2019
Time:
4:00 PM - 5:00 PM EDT
Event Description:
Presented by Doug Price, MA, President, Clinical Ink, and Alexis Gabard, MS, MBA, Director of Study Operations, Clinical Ink
Doug Pierce has more than 20 years of experience in digital forms technology, mobile data capture, healthcare workflow solutions and application design. Mr. Pierce co-founded Clinical Ink in 2007 to revolutionize clinical trials by eliminating the complexities and costs associated with paper-based data capture processes. In his role as President at Clinical Ink, Mr. Pierce leads the strategic direction, development and evolution of the Clinical Ink’s eSource platform.
Alexis Gabard is the Director of Study Operations at Clinical Ink. Mrs. Gabard has a MS in Counselor Education from UNCG and an MBA from the WFU School of Business. She has experience in the development and preclinical and clinical testing of psychophysiological interventions and medical devices. She has managed preclinical and clinical projects and over $17M in funding from NIH, the Department of Defense, and BARDA.
Doug Pierce has more than 20 years of experience in digital forms technology, mobile data capture, healthcare workflow solutions and application design. Mr. Pierce co-founded Clinical Ink in 2007 to revolutionize clinical trials by eliminating the complexities and costs associated with paper-based data capture processes. In his role as President at Clinical Ink, Mr. Pierce leads the strategic direction, development and evolution of the Clinical Ink’s eSource platform.
Alexis Gabard is the Director of Study Operations at Clinical Ink. Mrs. Gabard has a MS in Counselor Education from UNCG and an MBA from the WFU School of Business. She has experience in the development and preclinical and clinical testing of psychophysiological interventions and medical devices. She has managed preclinical and clinical projects and over $17M in funding from NIH, the Department of Defense, and BARDA.
